Showing 2491-2500 of 4671 results for "".
- Dermatologist Terrence A. Cronin Jr., MD, Named New AAD Presidenthttps://practicaldermatology.com/news/dermatologist-terrence-a-cronin-jr-md-named-new-aad-president/2461615/Terrence A. Cronin Jr., MD, FAAD, is the new President of the American Academy of Dermatology. He will start his one-year term at the close of the Academy's Annual Meeting. Dr. Cronin will also hold the same position for the American Academy of Dermatology Association, a sister
- Kenneth J. Tomecki, MD, FAAD is New President of the AADhttps://practicaldermatology.com/news/kenneth-j-tomecki-md-faad-is-new-president-of-the-aad/2460723/Kenneth J. Tomecki, MD, FAAD is now president of the American Academy of Dermatology (AAD). During his one-year term, Dr. Tomecki will lead the world’s largest dermatologic society, representing more than 20,000 physicians specializing
- Meet JAAD's New Editor Dirk M. Elston, MDhttps://practicaldermatology.com/news/meet-jaads-new-editor-dirk-m-elston-md/2457918/Charleston, SC-based dermatologist Dirk M. Elston, MD, FAAD, is the next editor of the Journal of the American Academy of Dermatology. Dr. Elston, the journal’s current deputy editor, will step into his new role in July 2018, succeeding de
- Skin Cancer Expert Perry Robins, MD Joins Emerald's Advisory Boardhttps://practicaldermatology.com/news/skin-cancer-expert-perry-robins-md-joins-emeralds-advisory-board/2458574/New York City dermatologist Perry Robins, MD has joined Emerald Medical Applications Corp.’s advisory board. Emerald, an Israeli-based company, is developing DermaCompare™, a proprietary artificial intelligence free app 
- Leo Pharma's Adbry Reduces S. aureus Skin Colonization in Kids With ADhttps://practicaldermatology.com/news/leo-pharmas-adbry-reduces-s-aureus-skin-colonization-in-kids-with-ad/2461616/Leo Pharma’s Adbry (tralokinumab-ldrm) significantly reduced the abundance of Staphylococcus aureus in the lesional and non-lesional skin of adolescents with atopic dermatitis (AD) after 16 weeks, according to new data presented at the American Academy of Dermatology
- USPTO Grants Patents to TOOsonix A/S for HIFU Technologies in Dermatologyhttps://practicaldermatology.com/news/uspto-grants-patents-to-toosonix-as-for-hifu-technologies-in-dermatology/2461420/The United States Patent and Trademark Office (USPTO) granted TOOsonix A/S patents regarding its key high-intensity focused ultrasound (HIFU) technologies for dermatology The U.S. patent and already granted patents in Europe and China to complete the first phase of securing intellectual prop
- Hoth Therapeutics, Inc.’s BioLexa in AD: So Far, So Safehttps://practicaldermatology.com/news/hoth-therapeutics-incs-biolexa-in-ad-so-far-so-safe/2460853/Hoth Therapeutics, Inc.’s BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed, according to the safety results in Cohort 1 of its first in human clinical trial of the BioLexa platform to treat atopic dermatitis.
- TOOsonix A/S Rolls Out System ONE-M for Aesthetic Treatmentshttps://practicaldermatology.com/news/toosonix-as-rolls-out-system-one-m-for-aesthetic-treatments/2460449/TOOsonix A/S is launching its CE-marked System ONE-M for color-independent tattoo removal, solar lentigines, spider veins, angiomas, telangiectasia and other aesthetic conditions. System ONE-M is a focused ultrasound device operati
- Thumbs Down for Neothetics, Inc.'s LIPO-202; Stock Plummetshttps://practicaldermatology.com/news/thumbs-down-for-neothetics-incs-lipo-202/2458145/Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-concept trial. Neothetics Inc. shares droppe
- Soligenix, Inc.’s SGX302 (Synthetic Hypericin) Demonstrates “Clear Biological Signal” in Phase 2a PsO Studyhttps://practicaldermatology.com/news/sgx302-synthetic-hypericin-demonstrates-clear-biological-signal-in-phase-2a-pso-study/2461854/Soligenix, Inc.’s SGX302 (synthetic hypericin) showed a clear